USFDA Classifies Aurobindo Pharma Subsidiaries with VAI and OAI Statuses in 2026 Inspections
Aurobindo Pharma's subsidiaries received different classifications from the US FDA following inspections in 2026. The Telangana API facility of Apitoria Pharma was classified as 'Voluntary Action Indicated' (VAI), indicating objectionable conditions but no immediate regulatory action. Meanwhile, the US manufacturing facility of Lannett Company LLC was classified as 'Official Action Indicated' (OAI), signaling significant violations and recommended regulatory actions. Aurobindo Pharma stated these classifications do not affect its financials or operations and reaffirmed its commitment to quality compliance.
First-hand measurement across 2 sources
We measured how 2 outlets covered this story. No outlet gave this story a measurable political slant — there is no left–right reading to report. Overall sentiment is neutral (49/100). Lens Score 49/100.
Outlets measured: news18, economictimes. See how each one headlined and framed the same story in the source comparison below.
AI Analysis
Sentiment was consistent across outlets (48–50/100), indicating broadly factual reporting rather than editorialising.
Coverage timeline
economictimes broke this story on 11 Nov, 08:55 am. Other outlets followed.